<DOC>
	<DOC>NCT02581553</DOC>
	<brief_summary>This study will assess relative bioavailability of lesinurad/allopurinol fixed dose combination (FDC), its individual components and the effect of food.</brief_summary>
	<brief_title>Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability</brief_title>
	<detailed_description>The study comprises 2 parts. Part 1 will assess the relative BA of lesinurad/allopurinol FDC and monocomponents in fasted subjects. Part 2 will assess the effect of food on the PK of FDC tablets.</detailed_description>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Lesinurad</mesh_term>
	<criteria>Body mass index ranging between 18 kg/m2 and 40 kg/m2. Screening serum urate level is â‰¤ 7.0 mg/dL. Asian subject who has a positive test for the HLAB*5801 allele. History or suspicion of kidney stones. Estimated creatinine clearance, as determined at Screening, of &lt; 90 mL/min calculated by the CockcroftGault formula using ideal body weight. Undergone major surgery within 3 months prior to Screening. Donated blood or experienced significant blood loss (&gt; 450 mL) within 12 weeks prior to Day 1or has given a plasma donation within 4 weeks prior to Day 1. Inadequate venous access or unsuitable veins for repeated venipuncture. Received any strong or moderate enzymeinducing drug or product within 2 months prior to Screening.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>